Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

350R-2

Sigma-Aldrich

FOXP1 (EP137) Rabbit Monoclonal Primary Antibody

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352203
Le tarif et la disponibilité ne sont pas disponibles actuellement.

Source biologique

rabbit

Niveau de qualité

100
500

Conjugué

unconjugated

Forme d'anticorps

culture supernatant

Type de produit anticorps

primary antibodies

Clone

EP137, monoclonal

Description

For In Vitro Diagnostic Use in Select Regions

Forme

buffered aqueous solution

Espèces réactives

human

Conditionnement

vial of 0.1 mL concentrate (350R-24)
vial of 0.1 mL concentrate Research Use Only (350R-24-RUO)
vial of 0.5 mL concentrate (350R-25)
vial of 1.0 mL concentrate (350R-26)
vial of 1.0 mL concentrate Research Use Only (350R-26-RUO)
vial of 1.0 mL pre-dilute Research Use Only (350R-27-RUO)
vial of 1.0 mL pre-dilute ready-to-use (350R-27)
vial of 7.0 mL pre-dilute ready-to-use (350R-28)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (350R-28-RUO)

Fabricant/nom de marque

Cell Marque®

Technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500 (concentrated)

Isotype

IgG

Contrôle

lymph node, tonsil

Conditions d'expédition

wet ice

Température de stockage

2-8°C

Visualisation

nuclear

Informations sur le gène

human ... FOXP1(27086)

Description générale

Diffuse large B-cell lymphoma (DLBCL) most likely represents different clinicopathologic entities, which are difficult to separate using standard technique.[1][2] Diffuse large B-cell lymphoma (DLBCL) can be divided into the subtypes of germinal center B-cell–like (GCB), activated B-cell–like (ABC), and unclassified DLBCL.[2][3][4] The GCB and ABC subtypes have different pathogenetic mechanisms that will impact the development of targeted therapies.[3] Despite the robustness of gene expression profiling (GEP) in subclassifying DLBCL, GEP techniques are not applicable to the routine clinical practice due to the substantial time, technological expertise, and scarce resources required. Therefore, it is beneficial for the translational application of the GEP classification into protein expression by tumor cells to be developed through immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded tissues. Different approaches using immunophenotypic algorithms with small panels of antibody biomarkers have been developed to translate the robust information from molecular studies into a routine clinical platform,[5][6][7][8][9] using antibodies against CD10, BCL6, MUM1/IRF4, GCET1, FoxP1, LMO2, and BCL2. Therefore, FoxP1 is useful in subclassification of DLBCL and a high cutoff (80%) for FoxP1 is needed to achieve high specificity for the ABC subtype.

Qualité


IVD

IVD

IVD

RUO

Liaison

FoxP1 Positive Control Slides, Product No. 350S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Forme physique

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Notes préparatoires

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Autres remarques

For Technical Service please contact: 800-665-7284 or email: [email protected]

Informations légales

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (2008)
A A Alizadeh et al.
Nature, 403(6769), 503-511 (2000-02-17)
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in
Andreas Rosenwald et al.
The New England journal of medicine, 346(25), 1937-1947 (2002-06-21)
The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival. Biopsy samples of diffuse large-B-cell lymphoma from
George Wright et al.
Proceedings of the National Academy of Sciences of the United States of America, 100(17), 9991-9996 (2003-08-06)
To classify cancer specimens by their gene expression profiles, we created a statistical method based on Bayes' rule that estimates the probability of membership in one of two cancer subgroups. We used this method to classify diffuse large B cell
Lluís Colomo et al.
Blood, 101(1), 78-84 (2002-10-24)
To analyze the relationship between immunophenotyping profile and main clinicopathological features and outcome in diffuse large B-cell lymphoma (DLBCL), we studied 128 patients (59 men, 69 women; median age 65 years) consecutively diagnosed with de novo DLBCL in a single

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique